Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
April 2 (Reuters) - Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market. Brokerages estimate 2026 sales of...
Reuters